Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Inmed Pharmaceuticals IN (IN.TO)

Inmed Pharmaceuticals IN (IN.TO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 50,824
  • Shares Outstanding, K 172,284
  • Annual Sales, $ 0 K
  • Annual Income, $ -13,255 K
  • 60-Month Beta 2.68
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.27
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.09
  • Most Recent Earnings -0.02 on 03/31/20
  • Next Earnings Date 05/14/20
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.02
  • Number of Estimates 1
  • High Estimate -0.02
  • Low Estimate -0.02
  • Prior Year -0.02
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.19 +63.16%
on 04/29/20
0.37 -16.22%
on 05/13/20
+0.11 (+55.00%)
since 04/27/20
3-Month
0.17 +82.35%
on 03/23/20
0.37 -16.22%
on 05/13/20
-0.04 (-11.43%)
since 02/27/20
52-Week
0.17 +82.35%
on 03/23/20
0.46 -32.61%
on 05/28/19
-0.13 (-29.55%)
since 05/27/19

Most Recent Stories

More News
InMed Releases CBN Preclinical Results in Glaucoma

VANCOUVER , May 27, 2020 /PRNewswire/ -  InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting...

IMLFF : 0.2315 (+6.78%)
IN.TO : 0.31 (+6.90%)
InMed Pharmaceuticals Continues to Strengthen Biosynthesis Patent Family

VANCOUVER , May 19, 2020 /PRNewswire/ -  InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting...

IMLFF : 0.2315 (+6.78%)
IN.TO : 0.31 (+6.90%)
InMed Pharmaceuticals Reports Third Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update

VANCOUVER , May 14, 2020 /PRNewswire/ -  InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting...

IMLFF : 0.2315 (+6.78%)
IN.TO : 0.31 (+6.90%)
InMed Files PCT Patent Application for Neuroprotection in Glaucoma

VANCOUVER , May 12, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases...

IMLFF : 0.2315 (+6.78%)
IN.TO : 0.31 (+6.90%)
InMed Pharmaceuticals to Report Third Quarter Fiscal 2020 Financial Results and Business Update on May 14, 2020

VANCOUVER , May 8, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases...

IMLFF : 0.2315 (+6.78%)
IN.TO : 0.31 (+6.90%)
InMed to Present at Canaccord Genuity's 4th Annual Cannabis Conference

VANCOUVER , May 7, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting...

IMLFF : 0.2315 (+6.78%)
IN.TO : 0.31 (+6.90%)
InMed and Almac Group Developing Improved Cannabinoid Production Methods

VANCOUVER , May 5, 2020 /PRNewswire/ -  InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting...

IN.TO : 0.31 (+6.90%)
IMLFF : 0.2315 (+6.78%)
InMed Receives CTA Approval for Second Phase 1 Clinical Trial with INM-755

VANCOUVER , April 30, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), a clinical-stage pharmaceutical company developing medications targeting...

IN.TO : 0.31 (+6.90%)
IMLFF : 0.2315 (+6.78%)
InMed Announces Completion of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

VANCOUVER , April 1, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting...

IMLFF : 0.2315 (+6.78%)
IN.TO : 0.31 (+6.90%)
InMed Submits Clinical Trial Application to Evaluate INM-755 in Second Phase 1 Trial

VANCOUVER , March 24, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting...

IMLFF : 0.2315 (+6.78%)
IN.TO : 0.31 (+6.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Key Turning Points

2nd Resistance Point 0.34
1st Resistance Point 0.32
Last Price 0.31
1st Support Level 0.30
2nd Support Level 0.30

See More

52-Week High 0.46
Fibonacci 61.8% 0.35
Fibonacci 50% 0.31
Last Price 0.31
Fibonacci 38.2% 0.28
52-Week Low 0.17

See More

Business Summary

InMed Pharmaceuticals Inc is a Canada based pre-clinical stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based therapies combined with drug delivery systems. It is focused on the treatment of diseases including pain and inflammation, dermatology,...

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar